Gut-Associated Lymphocyte Trafficking
- Conditions
- HIV-1 Infection
- Interventions
- Other: Peripheral blood and intestinal biopsies will be collected
- Registration Number
- NCT02906137
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Brief Summary
The gut immune barrier is not fully restored in HIV-1-infected subjects despite they were receiving antiretroviral treatment. This leaky gut leads to microbial translocation from the gut lumen into the bloodstream that fuels deleterious systemic inflammation. The chemotaxis axes that allow T lymphocytes to migrate from the blood to the gut mucosa in order to reconstitute the mucosal immune barrier seems altered in treated HIV-1-infected subjects.This study aims at better understanding the mechanisms involved in this lack of mucosal immune restoration.
- Detailed Description
Pathophysiological study in human subjects, comparative, national, multicentric and prospective. Peripheral blood and intestinal biopsies will be collected.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HIV-1 infected subjects Peripheral blood and intestinal biopsies will be collected 40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France: * 15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling * 15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling * 10 subjects will have both a gastroscopy and a coloscopy Uninfected-controls Peripheral blood and intestinal biopsies will be collected 40 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France: * 10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling * 10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling * 20 subjects will have both a gastroscopy and a coloscopy
- Primary Outcome Measures
Name Time Method Immune status: Measure of the frequencies of Th1 in peripheral blood and gut mucosa. Baseline The frequencies of Th1 will be measured by flow cytometry.
Immune status: Measure of the frequencies of Th17 in peripheral blood and gut mucosa. Baseline The frequencies of Th17 will be measured by flow cytometry.
Immune status: Measure of the frequencies of Th22 in peripheral blood and gut mucosa. Baseline The frequencies of Th22 will be measured by flow cytometry.
- Secondary Outcome Measures
Name Time Method Microbial translocation : Quantification of soluble soluble CD163 in plasma. Baseline The quantification of CD163 will be realised by Enzyme-Linked Immunosorbent Assay (ELISA) .
Immune status: Quantification of cytokines in blood and gut mucosa. Baseline The quantification of cytokines will be measured by immuno-histochemistry.
Immune status: Quantification of chemiokines in blood and gut mucosa. Baseline The quantification of chemiokines will be measured by immuno-histochemistry.
Microbial translocation : Quantification of soluble CD14 in plasma. Baseline The quantification of CD 14 will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).
Microbial translocation : Quantification of 16S RNA. Baseline The quantification of 16S RNA will be realised by real-time Polymerase Chaine Reaction (qPCR).
Microbial translocation : Quantification of Intestinal-type Fatty Acid-Binding Protein (I-FABP) in plasma. Baseline The quantification of Intestinal-type Fatty Acid-Binding Protein (I-FABP) will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).
Microbial translocation : Quantification of Lipopolysaccharide Binding Protein (LBP). Baseline The quantification of Lipopolysaccharide Binding Protein will be realised by Enzyme-Linked Immunosorbent Assay (ELISA).
Trial Locations
- Locations (2)
Hôpital Purpan - Service de Médecine Interne
🇫🇷Toulouse, France
Hôpital Purpan - Service des maladies Infectieuses
🇫🇷Toulouse, France